Rezolute plunges 90% as Phase 3 sunRIZE trial for low BP fails

Rezolute shares fell nearly 90% after its Phase 3 sunRIZE trial for ersodetug failed to meet primary and secondary endpoints in treating low blood pressure. The stock hit its lowest level since February 2024 before trading was halted. The company said its separate Phase 3 upLIFT study remains ongoing, with results expected in late 2026.